Eye Diseases Statistics in US 2026 | Treatments & Key Facts

What Do Eye Disease Statistics Tell Us About the US in 2026?

Eye and vision diseases affect tens of millions of Americans and represent one of the most significant — and most preventable — sources of disability and quality-of-life loss in the country. In 2026, the scale of the challenge is coming into sharper focus than ever before, as an ageing population drives the prevalence of age-related conditions relentlessly upward while improvements in screening technology, pharmaceutical innovation, and AI-powered diagnosis are simultaneously transforming what is achievable clinically. According to the Prevent Blindness national surveillance data drawing on the CDC’s Vision and Eye Health Surveillance System (VEHSS), as of 2017 approximately 7.08 million Americans were living with uncorrectable visual acuity loss or blindness — a figure that the National Eye Institute (NEI) projects will effectively double by 2050 as the baby boomer generation ages through the highest-risk decades for conditions like age-related macular degeneration, glaucoma, cataracts, and diabetic retinopathy. The US retinal disorder treatment market alone was valued at $7.1 billion in 2024 and is projected to grow to $13.1 billion by 2034, while the global ophthalmology drugs market — in which North America holds a 61.1% revenue share — is growing from $19.52 billion in 2025 to a projected $26.28 billion by 2030.

What makes the 2026 US eye disease statistics particularly important is the combination of demographic inevitability and clinical opportunity running in parallel. The demographic trajectory is sobering: with 19.83 million Americans already living with age-related macular degeneration, 9.6 million with diabetic retinopathy, 4.22 million with glaucoma, and a cataract burden that makes the condition the most common cause of reversible blindness globally, the pressure on the US eye care system is structural rather than episodic — it is baked into the ageing of the population and the rising prevalence of diabetes. Yet the clinical opportunity is equally real: early detection and treatment can prevent more than 90% of diabetes-related visual impairment, according to CDC analysis; autonomous AI-based diabetic retinopathy screeners can detect sight-threatening disease with up to 96% sensitivity; and a new generation of anti-VEGF biologics, gene therapies, and sustained-release ocular implants are extending what is achievable in retinal medicine to a degree that would have been unimaginable a decade ago. Understanding the statistics behind both the scale of the problem and the potential of available solutions is essential for patients, clinicians, policymakers, and anyone with a stake in American public health in 2026.

Interesting Facts About Eye Diseases in the US in 2026

Source: Prevent Blindness / CDC Vision and Eye Health Surveillance System (VEHSS); National Eye Institute (NEI), NIH; Grand View Research Diabetic Retinopathy Market (2026); MarketsandMarkets Ophthalmology Drugs Report (November 2025); Global Market Insights Retinal Disorder Treatment Market (May 2025); VisionCenter.org Global Eye Care Technology Statistics (March 21, 2026); iHealthcareAnalyst AMD Market (March 2, 2026); Grand View Research Ophthalmic Drug Delivery Systems Market (2025); StatPearls Publishing (updated 2026); JAMA Ophthalmology / PMC Bayesian Meta-analysis

The 15 facts above map the full scope of the US eye disease burden in 2026 — from the staggering 20 million Americans living with AMD to the clinically transformative potential of AI screening tools achieving 96% sensitivity for diabetic retinopathy. What connects these two endpoints is a healthcare system whose ambition and innovation outpace its systematic delivery: early detection can prevent the vast majority of diabetic vision loss, but the US only reaches 65% of diabetic patients with retinopathy screening — a 35% gap that translates directly into preventable blindness cases each year. The $7.1 billion US retinal disorder treatment market absorbing the consequences of late-stage disease reflects not just the biological burden of retinal conditions but a structural failure of preventive care access and uptake that spending more on treatment cannot resolve.

The anti-VEGF revolution is simultaneously the most important development in retinal medicine in a generation and one of the most vivid illustrations of the access challenge in American eye care. Anti-VEGF injections like Eylea (aflibercept) and Vabysmo (faricimab) have genuinely transformed the prognosis for wet AMD and diabetic macular edema — conditions that reliably caused severe vision loss as recently as the early 2000s. But these are expensive treatments, typically requiring injections every 8–16 weeks for years, administered by retinal specialists in office or outpatient settings. The patients who benefit most — those aged 65 and over with wet AMD, or working-age adults with proliferative diabetic retinopathy — represent very different access and compliance challenges, and the data showing only 65% diabetic retinopathy screening coverage in the US suggests that many of the patients who will most need these advanced retinal treatments in the years ahead are not currently being identified early enough to make that treatment maximally effective.

Major Eye Diseases in the US 2026 | Prevalence by Condition

Major Eye Conditions — US Prevalence (2019–2022 Latest Data, Key Sources)
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
Age-Related Macular Degeneration  ████████████████████████████████████████  ~19.8–20M Americans
Diabetic Retinopathy               ████████████████████████████████████      9.6M (2021); 11M by 2030
Glaucoma                           ████████████████████████████████          4.22M (2022)
Cataracts                          ████████████████████████████████████████  Most common; 50%+ over 80
Dry Eye Syndrome                   ████████████████████████████████████████  ~16–20M Americans
Visual Acuity Loss / Blindness     ████████████████████                      7.08M (uncorrectable, 2017)
Diabetic Macular Edema             ████████████████████████████████          Subset of 9.6M DR patients
Refractive Errors (correctable)    ████████████████████████████████████████  Most common eye condition
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
Scale: Each █ ≈ relative US prevalence burden

Source: Prevent Blindness / VEHSS national surveillance data; NEI Eye Health Data and Statistics; Grand View Research Diabetic Retinopathy Market (2026); StatPearls Blindness (updated 2026); Global Market Insights; VisionCenter.org (March 2026)

The condition-by-condition breakdown reveals that the US eye disease landscape in 2026 is dominated by an age-related cluster of conditions — AMD, glaucoma, diabetic retinopathy, and cataracts — that share a common biological driver in the progressive cellular deterioration that accompanies ageing. AMD’s ~20 million affected Americans makes it the most prevalent serious eye disease in the country by a wide margin, but its internal distinction between wet AMD (approximately 10–15% of cases, involving abnormal blood vessel growth, now treatable with anti-VEGF) and dry AMD (approximately 85–90% of cases, involving slow retinal cell atrophy, for which only two treatments were FDA-approved as recently as 2023 — Syfovre and Izervay — both targeting geographic atrophy as an advanced dry AMD stage) is critically important for understanding the treatment landscape. For the majority of the 20 million with AMD, there remains no approved treatment for the underlying disease process — only monitoring, lifestyle modification, and nutritional supplementation (AREDS2 formula) are available for early and intermediate stages.

Glaucoma’s particular danger as a public health threat lies in the combination of high prevalence, slow asymptomatic progression, and irreversible damage: by the time many patients notice symptoms, significant optic nerve damage has already occurred. With 4.22 million adults diagnosed in 2022 and an estimated comparable number who have the disease but remain undiagnosed — glaucoma is sometimes called the “silent thief of sight” precisely because it causes no pain and no obvious symptoms in its early stages — the condition represents one of the clearest cases in US eye care where systematic screening, rather than symptom-driven clinical presentation, is the only reliable early detection mechanism. The advent of Optical Coherence Tomography (OCT) scanning, which can visualize the optic nerve and retinal nerve fiber layer with micrometer precision, has dramatically improved early glaucoma detection for patients who do access regular eye care — but access disparities mean that the communities with highest glaucoma risk (particularly African American adults, who have three to four times the prevalence of glaucoma compared to white adults) are often least likely to receive the regular comprehensive eye exams that would catch the disease early.

Eye Disease Treatments & Innovation in US 2026 | Key Advances

US Eye Disease Treatment — Key Market & Innovation Data (2025–2026)
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
Ophthalmology drugs market (2025)   ████████████████████████████████████████  $19.52B global; 61.1% N.America
Ophthalmic drug delivery (2025)     ████████████████████████████████████████  $16.99B global; 56.9% N.America
Retinal disorder treatment US (2024)████████████████████████████████████████  $7.1B; → $13.1B by 2034
AMD treatment market (2025)         ████████████████████████████████████████  $10.4B global → $16.2B by 2034
Diabetic retinopathy market (2024)  ████████████████████████████████████████  $9.48B global; 37.8% N.America
Anti-VEGF domination                ████████████████████████████████████████  41–52% of retinal procedures
AI retinopathy screening            ████████████████████████████████████████  Up to 96% sensitivity
OCT scanning adoption               ████████████████████████████████████████  Standard in 68%+ of ophthalmic depts
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
Scale: Each █ ≈ relative magnitude

Source: MarketsandMarkets Ophthalmology Drugs Report (November 2025); Grand View Research Ophthalmic Drug Delivery Systems Market (2025); Global Market Insights Retinal Disorder Treatment (May 2025); IMARC Group AMD Treatment Market; Grand View Research Diabetic Retinopathy Market (2026); VisionCenter.org (March 2026); FDA approval database; iHealthcareAnalyst (March 2026)

The treatment innovation landscape for US eye diseases in 2026 is defined by two parallel revolutions that are reshaping the field simultaneously. The first is pharmacological: the anti-VEGF era that began with bevacizumab and ranibizumab has matured into a second generation defined by extended dosing, bispecific mechanisms, and sustained-release delivery. Vabysmo (faricimab) — Roche’s bispecific antibody targeting both VEGF-A and Ang-2 — represents the most significant therapeutic advance in wet AMD and DME treatment since the original anti-VEGF approvals, offering extended dosing intervals that reduce the treatment burden for patients who have historically needed injections every 4–8 weeks for years or decades. Susvimo’s port delivery system, receiving FDA approval for diabetic macular edema in February 2025, goes further: it delivers sustained anti-VEGF therapy directly from an implanted intraocular reservoir, potentially replacing multiple annual injections with a single refill procedure every 6 months. The approval of Syfovre and Izervay for geographic atrophy in 2023 marked the first-ever disease-modifying treatment options for the large population with advanced dry AMD — a condition that previously had no approved therapy beyond nutritional supplementation.

The second revolution is diagnostic and preventive, driven by AI. The FDA-cleared autonomous AI screening systems for diabetic retinopathy — now achieving up to 96% sensitivity in real-world deployment — represent a clinically validated tool that can be deployed in primary care offices, endocrinology practices, and community health settings, bringing retinopathy screening to the 35% of diabetic Americans who currently fall outside the specialist care pathway that has historically been the gateway to diagnosis. The implications for public health are substantial: if the gap between the US’s 65% screening rate and the UK’s 80% rate were closed through broader AI-assisted screening deployment, tens of thousands of Americans could receive earlier intervention for sight-threatening diabetic retinopathy each year — preventing a significant proportion of the estimated cases that progress to severe vision loss annually. Combined with OCT’s ability to detect early glaucoma and AMD changes before symptoms appear, the technology now exists to fundamentally shift US eye care from a reactive to a preventive model — the question in 2026 is primarily one of access, payment reform, and healthcare system will, not scientific capability.

Disclaimer: The data research report we present here is based on information found from various sources. We are not liable for any financial loss, errors, or damages of any kind that may result from the use of the information herein. We acknowledge that though we try to report accurately, we cannot verify the absolute facts of everything that has been represented.